| Oct 31 |
Agios Pharmaceuticals: Q3 Earnings Snapshot
|
| Oct 31 |
Agios Reports Business Highlights and Third Quarter 2024 Financial Results
|
| Oct 30 |
Agios Pharmaceuticals Q3 2024 Earnings Preview
|
| Oct 23 |
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease
|
| Oct 17 |
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
|
| Oct 10 |
4 Analysts Have This To Say About Agios Pharmaceuticals
|
| Sep 27 |
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
|
| Sep 27 |
Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal
|
| Sep 26 |
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
|
| Sep 17 |
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results
|
